**GASTROINTESTINAL STROMAL TUMORS: ABOUT 4 CASES AT THE ANGRE UNIVERSITY HOSPITAL (CÖTE D’IVOIRE)**

Henriette Ya Kissi Anzouan-Kacou1,2, Adjéka Stanislas Doffou1,2, Aboubacar Demba Bangoura1,2, Abdoulatif Yaogo1,2, Amoin Ange Christelle Degnon1, Innocents Boa Brou1, Alain Koffi Attia1,2

1 University Hospital of Angré, Abidjan, Côte d’Ivoire.

2 Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire.

Henriette Ya Kissi Anzouan-Kacou, MD, Hepato-gastroenterology Unit.

Adjéka Stanislas Doffou, MD, Hepato-gastroenterology Unit.

Aboubacar Demba Bangoura, MD, Hepato-gastroenterology Unit.

Abdoulatif Yaogo, MD, Hepato-gastroenterology Unit.

Amoin Ange Christelle Degnon, resident, Hepato-gastroenterology Unit.

Innocents Boa Brou, MD, Hepato-gastroenterology Unit

Alain Koffi Attia, MD, Hepato-gastroenterology Unit

**Corresponding author:** Henriette Ya Kissi Anzouan-Kacou, [kissihy@yahoo.fr](mailto:kissihy@yahoo.fr),

Tel: +225 0545350000

DOI:[**10.21608/ajgh.2024.292167.1055**](file:///E:\ajgh%202024\GASTROINTESTINAL%20STROMAL\publication\10.21608\ajgh.2024.292167.1055)**.**

Submission date:23 May 2024.

Revision date: 04 August 2024.

Acceptance date: 05 August 2024.

First online: 10 August 2024.

**ABSTRACT**

**Background**

Gastrointestinal stromal tumors are rare, sporadic connective tissue tumors. Very few cases have been reported in Africa, including Ivory Coast.

**Aim**

To report 4 cases of GIST at the Angré University Hospital in Ivory Coast.

**Patients and method**

It was a retrospective case series from April 2, 2020, to May 31, 2023, at the Hepato-gastroenterology Unit of the Angré University Hospital. GIST cases followed in consultation or hospitalization, confirmed by pathological examination and immunohistochemistry, were included. Data collection was based on consultation and hospitalization files, entered and processed anonymously. The variables studied were sociodemographic, clinical, paraclinical, and therapeutic data.

**Results**

We reported four cases of GIST. The patients had an average age of 61.7 years with a sex ratio of 1. The circumstances of discovery were a digestive hemorrhage, an epigastric mass, epigastric pain, and anorexia. The most common area was the stomach (3), and there was 1 case of mesentery GIST. Immunohistochemistry found three moderate to intense cytoplasmic and membrane markings by the anti-CD117 antibody, four markings for the anti-DOG1 antibody, three markings by the anti-CD34 antibody, and two membrane markings of the endothelial cell by the antibody anti-CD31. Treatment was surgical in 2 patients, followed by adjuvant treatment with Imatinib. The other two patients were treated with Imatinib alone for one and as neoadjuvant for the other, which will be followed by surgery if the tumor size regressed.

**Conclusion**

Gastrointestinal stromal tumors are rare pathologies with non-specific symptoms. For optimal management, the diagnosis must be confirmed by immunohistochemistry.

***Keywords:*** *GIST – Stromal tumors - Immunohistochemistry - Molecular biology - Imatinib – Africa- Mutation - Gastrointestinal bleeding - Abdominal mass – C-Kit.*

**Introduction**

Gastrointestinal stromal tumors (GIST) are rare, usually sporadic, connective tissue tumors traditionally located in the stomach or small intestine. These are the most common sarcomas [1, 2]. Clinically, it is essential to note that GISTs remain undiscovered for a long time until they reach a large size [3]. However, they are often found incidentally during radiological imaging or intraoperatively [4, 5]. Due to the development and advancement of immunohistochemical staining techniques and improvements in microscopic structural imaging, GISTs are becoming notable tumor entities with their specific markers and characteristics [6]. Although surgical resection is the potentially curative treatment for GIST, its management has been revolutionized by the approval of imatinib as an adjuvant and neoadjuvant treatment [7- 8]. In France, several studies have estimated their incidence at between 10 and 15 cases per year per million inhabitants, or approximately 600 to 900 new cases per year [9]. In Morocco, eight digestive stromal tumors were collected over six years [10]. In Ivory Coast, very few studies have been carried out with very few cases: the first study involved three cases of GIST, which were diagnosed after three acute gastrointestinal bleedings, and the second study concerns 1 case of GIST, which was discovered on abdominal computed tomography (CT), the objective of which was to describe the radiological semiology and management of this condition [11,12]. We report a case series of 4 GIST in a tertiary hospital in Abidjan, Côte d’Ivoire.

**MATERIAL AND METHOD**

**Type, setting, and period of study**

This retrospective case series study was conducted at the Hepato-Gastro-Enterology (HGE) Unit of the Internal Medicine and Geriatrics Department of the Angré University Hospital from April 2, 2020, to May 31, 2023.

**Selection criteria**

**Inclusion criteria**

Our study included cases of GIST followed in the HGE Unit of the Angré University Hospital and confirmed by pathological examination and immunohistochemistry.

**Exclusion criteria**

Our study did not include cases of gastrointestinal tumors whose diagnosis was not confirmed by pathological examination or whose files were incomplete.

**The variables studied**

* Socio-demographic characteristics: age, gender, profession, level of education, residence, marital status
* Clinical characteristics: reason for consultation or hospitalization, functional signs, history, physical signs
* Paraclinical characteristics: digestive endoscopy, pathological examination, immunohistochemical examination, thoracic and abdominopelvic scan
* Treatment: medical, surgical, targeted therapy
* Evolution: favorable, unfavorable, death

**Support and data collection**

Data were collected from consultation and hospitalization records, entered and processed anonymously.

**Data entry and analysis**

To exploit these data, we established medical observations, including sociodemographic, clinical, paraclinical, and therapeutic data and the resulting evolution.

**Ethical aspect**

Ethical aspects and professional conduct were respected. The data were collected, entered, and processed anonymously.

**Conflict of interest**

No conflict of interest.

**RESULTS**

We collected 4 cases of GIST during the study period, whose observations were reported.

**case #1**

Patient aged 56, teacher, hospitalized from 04/12/2021 to 04/23/2021 for upper gastrointestinal bleeding (UGIB). The onset of the symptoms dates to approximately ten days before his hospitalization, with the sudden onset of a very abundant UGIB externalized in the form of hematemesis and hematochezia. There was a hemodynamic impact, such as dizziness and loss of consciousness. All preceded by diffuse abdominal pain without fever. She also reports a deterioration in her general condition, such as weight loss amounting to 7 kg in 4 months. The patient was evacuated to the medical emergency room, where the biological assessment showed a hemoglobin level of 3.9 g/dl and the hematocrit was 11.9%. The patient benefited from resuscitation measures with several packed blood transfusions. She has had a history of high blood pressure for three years on perindopril/amlodipine 8/10 mg, cardio aspirin 100 mg, and is a fan of traditional treatment based on decoctions. A physical examination found a hemodynamically stable patient with a soft, symmetric, and non-tender abdomen without distention and palpable masses or melena on rectal examination. There were no signs of portal hypertension or hepatocellular insufficiency. The performed EGD revealed a fundic polyp 60 mm in diameter, with a regular surface, inflammatory with a non-hemorrhagic ulcer at its apex (fig 1). The pathological study of the biopsies carried out was in favor of a low-grade GIST of Miettinen malignancy of the stomach. In the immunohistochemical analysis, the cells strongly expressed the anti-CD34 antibody and weakly the anti-DOG1 antibody, posing the diagnosis of a gastrointestinal stromal tumor of low malignancy. A resection was performed by removing the cancer and respecting 2 cm of healthy margin. A thoracic-abdominal-pelvic CT scan was performed three months after the operation and did not reveal any thoracic-abdominal-pelvic tumor. However, it revealed hetero-nodular hypertrophy of the right thyroid lobe; the pathological examination after the cyst puncture of the thyroid nodule revealed a suspicious malignancy aspect (category C5, according to the terminology of BETHESDA 2017). The patient underwent a thyroidectomy in June 2022 with simple post-operative outcomes. An EGD control performed 06 months later came back normal, and the pathological examination of systematic antral (3) and fundal (2) gastric biopsies revealed the presence of chronic antral gastritis (3/3), non-atrophic., active (2/3), without intestinal metaplasia, not associated with follicular gastritis. Severe presence of *Helicobacter pylori* (3/3). Chronic fundic gastritis (3/3), non-atrophic, active (2/3), without intestinal metaplasia, not associated with follicular gastritis—average presence of *Helicobacter pylori* (2/3). There was no dysplasia and no histological sign of malignancy on the fragments examined. The patient received concomitant quadruple therapy (metronidazole 500 mg x 2/day + amoxicillin 1g x 2/day + clarithromycin 500 mg x 2/day + Rabeprazole 20 mg x 2/day) for 14 days for *Helicobacter pylori* eradication. The patient's clinical and paraclinical evolution was marked by good general condition.



Fig1. Endoscopic view of fundic polyp.

**case #2**

A 45-year-old patient without any medical-surgical history was referred on 09/21/2021 to manage an epigastric mass. The onset of symptoms dates back approximately two months, with the gradual onset of a non-painful epigastric mass associated with a general condition deterioration such as unquantified weight loss without any notion of intestinal transit disorder. The physical examination revealed a patient with a WHO performance status score of 1, a large mass 15 cm in diameter located in the left hypochondrium. An abdominal CT scan showed a large tissue mass developed at the expense of the Celio-mesenteric region. Pathological examination after carrying out a transcutaneous biopsy of the mass revealed a histological appearance suggestive of a GIST of the mesentery. On immunohistochemical examination:

* The anti-CD117 antibody moderates cytoplasmic and membrane marking.
* intense cytoplasmic and membrane marking by the anti-DOG1 antibody.
* intense membrane marking by the anti-CD34 antibody.
* membrane marking of endothelial cells by the anti-CD31 antibody,

Confirming the morphological diagnosis of GIST of the mesentery. Remote extension assessment (EGD, colonoscopy, thoracic-abdominopelvic CT scan) found no metastases. Furthermore, the tumor was classified as locally advanced and inoperable. A multidisciplinary consultation meeting of surgeons, oncologists, radiologists, and anatomopathological decided:

* treatment with targeted therapy based on Imatinib 400 mg per day,
* a clinical and paraclinical evaluation every three months showed a satisfactory clinical condition and regression of the tumor, which went from 15 cm to 6 cm on the last abdominal CT scan carried out in April 2023.
* R0 surgery will be re-discussed if the tumor regression is more than 80% satisfactory.

**Case #3**

The patient, aged 90, is a retired nurse. She has been followed since April 2021 for anorexia. The onset of symptoms dates to approximately three months before his admission, with the progressive onset of deterioration in general conditions such as unquantified weight loss, asthenia, and anorexia. She has hypertension treated by amlodipine, diabetic on galvusmet. She has a history of hysterectomy in 1982 for uterine fibroids. The clinical examination showed a patient with WHO performance status 2 with a BMI = 22.89 kg/m2 without dehydration or malnutrition. There was no jaundice or anemia. She had painless bilateral lower extremity pitting edema. The abdomen was soft and painless, without hepatomegaly or splenomegaly. There was no Troisier lymph node. The EGD revealed a large polyp measuring 10 cm under the ulcerated heart (figure 2). The pathological examination of the biopsies concluded with a histological appearance suggestive of a GIST associated with reactive gastritis without *Helicobacter pylori*. The immunohistochemistry study showed at the level of tumor cells:

* moderate to intense cytoplasmic and membrane staining by the anti-CD117 antibody
* moderate to intense cytoplasmic and membrane labeling by the anti-DOG1 antibody
* intense membrane marking by the anti-CD34 antibody
* membrane marking of endothelial cells by the anti-CD31 antibody

Thus, the diagnosis of stomach GIST was confirmed. A thoracic-abdominopelvic CT scan showed a multicystic liver without secondary pleuropulmonary localization. Medical treatment with Imatinib 400 mg/day and regular monitoring every three months was prescribed. The quarterly paraclinical evaluation showed a discreet increase in the size of the hepatic biliary cyst of segment VI and bilateral basal lung disease. Furthermore, the general condition was good after two years.




Fig 2. Endoscopic view: Subcardiac polyp in retroversion position.

**Case #4**

A 56-year-old patient, Steward, is followed in consultation for the management of a digestive tumor. The history of the disease dates to March 2017, with the occurrence of chronic epigastric pain radiating to the back and not calmed by PPI treatments. Physical examination was unremarkable. EGD revealed a Siewert II circumferential esophagogastric junction tumor. The histological study suggested a GIST of low malignancy. The immunohistochemistry study showed:

* the anti-CD117 antibody gives an obvious positive marking on the entire tumor proliferation
* the anti-DOG1 antibody gives a more discreet and more focal positive marking
* there was no staining with the anti-desmin antibody
* the ant-Ki67 antibody reveals a shallow proliferation index (less than five mitoses on high power fields).

Confirming GIST with low mitotic index. Furthermore, a thoracic-abdominopelvic CT scan did not reveal any secondary location of the tumor. Distal esophagectomy and total gastrectomy were performed with an esophagojejunal anastomosis. The postoperative course was marked by an esophagojejunal fistula, which dried up. The patient was discharged after 30 days of hospitalization. Histological examination of the surgical specimen suggested a low-grade malignancy GIST, which immunohistochemistry confirmed. The patient was subsequently referred to oncology and placed on adjuvant treatment with Imatinib, followed by regular clinical, CT scan, and biological monitoring. The progress report seven months after esophagogastrectomy and six months after medical treatment: EGD did not show any lesion on esophago-duodenal montage; the histological study suggested chronic follicular duodenitis without villous atrophy, non-specific chronic jejunitis and an absence of malignant tumor proliferation. Another EGD control carried out 12 months later did not show any macroscopic lesion of tumor recurrence but revealed a sub-centimeter sessile polyp on the anastomosis jejunal side. The histological typing showed a pseudo polyp chronic inflammatory disease of the jejunum. A thoracic-abdominal-pelvic CT scan showed segmental thickening of the small intestine in the left hypochondrium, which prompted a CT enterography scan, which came back normal. The evolution was good, with treatment continuing after 06 years.

**Observations summaries**

In our study, the median age of the patients was 61.7, ranging from 45 to 90. The sex ratio was 1. The most common site was the stomach (75%), and there was 1 case of mesentery GIST (25%). Demographic and clinical data are summarized in Tab 1.

Tab1. Demographic and clinical features.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
| Age (year) | 56 | 45 | 90 | 56 |
| Gender | Male | Female | Female | Male |
| Primary symptom | Upper gastrointestinal bleeding | Epigastric mass | Anorexia | Epigastric pain |
| Location of GIST | Stomach | Mesentery | Stomach | Esophagogastric junction |

The pathological results are summarized in Tab 2.

Table 2. GIST’s pathological characteristics

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **case 1** | **case 2** | **case 3** | **case4** |
| **Histology** | Low-grade malignancy of gastric GIST *Helicobacter pylori infection* | GIST of the mesentery | GIST associated with reactive gastritis without *Helicobacter pylori* | Low-grade GIST |
| **Immunohistochemistry** | The cells strongly expressed the anti-CD34 antibody, weakly the anti-DOG1 antibody | - Moderated cytoplasmic and membrane marking by the anti-CD117 antibody.  - Intense cytoplasmic and membrane marking by the anti-DOG1 antibody  - Intense membrane marking by the anti-CD34 antibody  -Membrane marking of endothelial cells by the anti-CD31 antibody | - Moderate to intense cytoplasmic and membrane marking by the anti-CD117 antibody  - Moderate to intense cytoplasmic and membrane marking by the anti-DOG1 antibody  - Intense membrane marking by the anti-CD34 antibody  - Membrane marking of endothelial cells by the anti-CD31 antibody | -The anti-CD117 antibody gives an obvious positive marking on the entire tumor proliferation  -The anti-DOG1 antibody gives a more discreet and more focal positive marking  -There was no marking with the anti-desmia antibody |
| **Mitotic index** |  |  |  | The anti-Ki67 antibody reveals a shallow proliferation index (less than five mitoses on high magnification fields) |

The treatment was medico-surgical (Tab 3).

Table 3. **GIST treatments**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Case1** | **Case 2** | **Case 3** | **Case 4** |
| **treatment** | R0: tumor resection+ Imatinib 400mg | Imatinib 400mg | Imatinib 400mg | Esophagogastrectomy + Imatinib 400mg/J |

**DISCUSSION**

Our work was a retrospective cross-sectional study, reporting a series of 4 cases in which the diagnosis of digestive stromal tumor had been retained.

Our series of 04 cases found in 3 years was low, as were those reported in Tunisia [13], which found 25 cases in 20 years, or Morocco, which found 06 cases in 5 years [14]. Ahmadou in Mali [15] reported 25 cases in 10 years. This low number of cases reported in these studies reflects the rarity of this digestive tumor in our African countries, as described in Western literature [1, 2]. The median age of our case series was 61.7 years, which is without significant difference from that found in the Malian, Moroccan, Chinese, and Korean series, which ranged from 54.9 to 61.1 years [13, 15- 17]. However, it is lower than that of Batcham et al. [ 12] in Ivory Coast and Hinz et al. [ 70 18] in Germany, who found respectively 65 years and 64 years, and higher than that found by Hassan in Qatar in 2014, whose age was 48.4 ± 13.7 [19]. GISTs can be found at any age, in young people but exceptionally in children [20 - 21]. Regarding gender, even if certain international studies show a slight male predominance, we note that the sex ratio is close to 1 [22 - 24]. It is like our research, which found an identical distribution between the two genders.

Although GISTs can remain asymptomatic for a long time, their discovery is often fortuitous. Clinical signs and complications generally appear when the tumor size is large. This method of revelation represents approximately 20 to 30% of diagnoses, and the discovery mainly takes place during a digestive endoscopy, a CT scan, or an abdominal surgical procedure [3-4, 9]. Great clinical diversity is noted; the symptoms differ depending on the location; they can manifest as digestive bleeding [25], abdominal pain, an abdominal mass, an obstructive syndrome, or, more rarely, hemoperitoneum [26 - 27]. Our series found a digestive hemorrhage, an abdominal mass, and a gastric tumor as the circumstances of discovery. We did not have any case of chance discovery circumstances, unlike Ahmadou in Mali [15], who noted 4 cases of chance discovery. Tumors increasingly develop from the stomach (60 to 70%), small intestine (20 to 30%), large intestine (10%), rectal and peri-anal region (<5%), esophagus, mesentery, appendix (<1%) [26]. In our series, the stomach represented the most frequent location (3 cases) and 1 case for the mesentery, a rare location.

The endoscopic appearance of GIST is not very specific, generally that of a regular nodule, with a submucosal appearance because it is covered by normal mucosa. Nevertheless, we must evoke this diagnosis in the stomach by argument of frequency. The tumor may also be ulcerated at its apex [9]. In our series, case no. 1 presented the same appearance of a fundic nodule 60 mm in diameter, with a regular surface, inflammatory ulcerated at its apex, probably having bled. Moreover, endophytic stromal tumors quickly form a mass bulging into the intestinal lumen, which can appear mobile or polypoid [28]. Confirmation of the diagnosis is made in most cases on analysis of the surgical specimen.

Ultrasound endoscopy is the best examination to characterize esophagi-gastroduodenal or rectal submucosal lesions [29]. In our series, none of the patients had performed an ultrasound endoscopy, which was unavailable in our country's public or private hospitals.

In our series, no patient performed an FDG Pet-Scan as it was unavailable in our country during the study period; however, the first nuclearmedicine center was inaugurated on July 25, 2023, in Abidjan. The extension workup was limited to a thoracic-abdominopelvic CT scan, which found no pulmonary, hepatic, or peritoneal metastases. However, one patient presented with hetero-nodular enlargement of the right thyroid lobe, the pathological examination of which, after cyst puncture of the thyroid nodule, revealed an aspect suspicious of malignancy.

GISTs expressed CD 117 or c-Kit on immunohistochemistry in 90 to 95% of cases [30]. Other markers are recommended in case of CD 117 negativity (CD34, NSE, H caldesmon, anti-actin, protein S100, DOG 1, PKC theta) [30 - 32]. In our series, immunohistochemistry found three moderates to intense cytoplasmic and membrane markings by the anti-CD117 antibody, i.e., 75%, four markings for the anti-DOG1 antibody, i.e., 100%, three markings by the anti-CD34 antibody 75. % and two membrane markings of the endothelial cell by the anti-CD31 antibody, i.e., 50%. In the Malian study, the marking was positive for CD117 in 100% of cases, CD34 in 8%, and DOG1 in 8% of cases [15].

Several prognostic classifications exist, but the most important ones are those of Joensuu [33] and Miettinen [34]. In our series, observation no. 4 reveals a shallow proliferation index by the ant-Ki67 antibody. Ahmadou in Mali [15] found a progressive risk according to the Miettinen classification: high (52%), intermediate (24%), low (8%), and deficient (16%).

In our series, the treatment was surgical and medical, depending on the case. First, about localized tumors, treatment was initially surgical with R0 resection. Case No. 1 involved performing a lumpectomy, and case No. 4 performed an esophagogastrectomy with esophagojejunal anastomosis, then medical adjuvant treatment based on Imatinib 400 mg/day. According to Batcham et al. [12] study in Ivory Coast, the surgical treatment consisted of surgical removal of the mass and a partial gastrectomy followed by chemotherapy based on Imatinib. Ellara et al. [13] in Tunisia reported 25 cases of GIST, 16 of which were localized and all treated surgically. In Mali [15], tumor excision was carried out in 76% of cases, and Imatinib, available free of charge, was prescribed in 16% of cases.

The alternative of neoadjuvant treatment is reasonable when the resection seems important or uncertain preoperatively to limit the initial surgical procedure and increase the chances of complete resection. Surgery is considered when the maximum response is observed, generally after 6 to 12 months of treatment [2]. It was the case of observation no. 2 of our series; the patient was put under neoadjuvant treatment with Imatinib 400 mg/day for a large tumor of approximately 15 cm in diameter, which decreased to 6 cm at the last abdominal scan carried out in April 2023. This quarterly clinical and paraclinical evaluation will continue, and then R0 surgery will be discussed again in a multi-disciplinary consultation meeting if the evolution is more than 80% satisfactory.

According to Mosnier et al. [35], in almost half of the cases, stromal tumors are immediately clinically pejorative, either because there is a locoregional invasion or because there are metastases. Malignancy can become evident more than ten years after the initial resection. In 75% of cases, recurrences and death are marked by peritoneal implants and liver metastases, the two being often associated. Extra-abdominal metastases exist in 25% of cases. Lymph node metastases are rare. In our series, the patients were all in good health, with follow-ups ranging from 2 years for some to 6 years for others.

The study's limitations were the biases inherent in a retrospective study: selection bias and recall bias. The difficulties were the chronology of events to arrive at the diagnosis, the insufficiency of data found in specific files, and the insufficiency of the technical platform in hospitals: failure to carry out specific additional examinations such as echoendoscopy and 18F-fluoro-2-deoxy-D-glucose (FDG) PET-Scan.

**Conclusion**

Gastrointestinal stromal tumors are rare in our unit. Our study shows that the median age of our patients is 61.7 years, and GIST occurs in both men and women. The symptoms are not very specific and are highlighted by gastrointestinal bleeding and abdominal mass with a predominant gastric location (75%). The definitive diagnosis is made by anatomopathological examination combined with immunohistochemistry of biopsies and surgical specimens. Management is multidisciplinary and based on surgery, which constitutes the only potentially curative treatment and imatinib, a tyrosine kinase inhibitor. Due to the very often poor prognosis of this tumor, monitoring is an essential aspect of patient care.

**Footnotes.**

Ahmed Fathy (Assistant professor of internal medicine), Hayam Rashed (professor of pathology), Mohamed Emara (Professor of gastroenterology, hepatology, and infectious diseases), and Sara Salem (lecturer of internal medicine, gastroenterology, and hepatology unit) were the peer reviewers.

**E- Editor:** Salem Youssef Mohamed, Osama Ahmed Khalil, Amany Mohammed.

**Copyright ©.** This open-access article is distributed under the Creative Commons Attribution License (CC BY). It may be used, distributed, or reproduced in other forums, provided the original author(s) and the copyright owner(s) are credited. The original publication in this journal must be cited according to accepted academic practice.

**Disclaimer:** The authors' claims in this article are solely their own and do not necessarily represent their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product evaluated in this article or its manufacturer's claim is not guaranteed or endorsed by the publisher.

**Ethics Approval and Consent to Participate**: The Institutional Review Board Committee approved the experimental protocol.

**Consent for publication**: the patients in this research gave written informed permission to publish the data in this study.

**Data and materials availability:** The datasets used or analyzed during the current study are available from the corresponding author upon reasonable request.

**Competing interests**: The authors declare that they have no competing interests.

**Funding**: This study had no funding from any resource.

**Authors’ contributions**

Henriette Ya Kissi Anzouan-Kacou, Adjéka Stanislas Doffou were responsible for conception and revision. Aboubacar Demba Bangoura, Abdoulatif Yaogo, and Amoin Ange Christelle DegnonTou interpreted and analyzed data. Innocents Boa Brou and Alain Koffi Attia wrote the manuscript, which was revised and approved by all co-authors.

**Acknowledgments:** The authors would like to thank the members of the pathology department of Sidi Bel Abbes Hospital for their invaluable support, guidance, and educational insight.

This work was done according to the CARE guidelines.

**Ethical approval:** All procedures involving human participants followed the institutional and national research committee's moral standards, the 1964 Helsinki Declaration, and its later amendments or comparable ethical standards. All authors declare that consent was obtained from the patient (or other approved parties) to publish this case report and accompanying images.

**References**

1. Thésaurus National de Cancérologie Digestive. Disponible en ligne : [https://www.snfge.org/tncd](http://www.snfge.org/tncd).
2. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumors: ESMOEUROCAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:20-33.
3. Zhao X, Yue C. Gastrointestinal stromal tumor. J Gastrointest Oncol 2012; 3(3):189-208.
4. Gerrish ST, Smith JW. Gastrointestinal stromal tumors diagnosis and management: a brief review. [Ochsner J](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096364/) 2008 Winter; 8(4): 197–204.
5. Kermansaravi M, Rokhgireh S, Darabi S, Pazouki A. Laparoscopic total gastrectomy for a giant gastrointestinal stromal tumor (GIST) with acute massive gastrointestinal bleeding: a case report, Wideochir Inne Tech Maloinwazyjne 12 (3) (2017) 306-10. https://doi.org/10.5114/wiitm.2017.67997
6. Mckey R, Alskafi M, Khatoun H, Salame H, Ezzedine S. Complexity of Giant GIST Case Series and Review of the Literature. *Open Journal of Gastroenterology* 2022; 12, 137-152. doi: [10.4236/ojgas.2022.126014](https://doi.org/10.4236/ojgas.2022.126014).
7. Landi B, Blay JY, Bonvalot S et al. Thésaurus National de Cancérologie Digestive (TNCD). Dig Liver Dis. 2019; 51(9):1223-31. Https:// doi. Org/ 10. 1016/j. dld. 2019. 07. 006.
8. Doyon C, Sidéris L, Leblanc G, Leclerc YE, Boudreau D, Dubé P. Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor: Results of a Phase II Trial. Int J Surg Oncol. 2012; 2012:761576. doi: 10.1155/2012/761576. Epub 2012 Dec 17. PMID: 23316352; PMCID: PMC3534224.
9. Landi B, Bouché O, Guimbaud R, Chayvialle JA. Gastrointestinal stromal tumors (GIST) < 5 cm in size: review of the literature and expert propositions for clinical management. Gastroenterol Clin Biol 2010; 34: 120-33.
10. Oumnia Forsi : Les Tumeurs Stromales Gastro-Intestinales au Service de Médecine Interne du CHU Mohamed VI de Marrakech et du CHU Avicenne de Rabat. Thèse Med: Rabat, 2011; n°111.
11. N N’Dri, MF Diakite, JB Okon et al. Trois mélénas révélant les trois premiers cas de tumeurs stromales gastro-intestinales à Abidjan (Côte d’Ivoire). Journal Africain d'Hépato-Gastroentérologie 2012 ; 6 : 259-263.
12. Batcham AW, Le Dion A, N’guessan FE, Kouamé N. Tumeur Stromale Gastro-Intestinale (GIST) géante : Diagnostic Et Prise En Charge D’un Cas À Abidjan. Journal de Radiologie et de Médecine Nucléaire d’Afrique 2022 ; 1(2) :100-103. N° ISSN. 2791-3015.
13. Hellara O, Toumi O, Hadhri R et al. Caractéristiques épidémiologiques, cliniques thérapeutiques et évolutives des tumeurs stromales digestives : à propos de 25 cas. La Tunisie Médicale 2014 ; 92 (6) : 391-398.
14. Benchaji I. Les tumeurs stromales gastro-intestinales expérience de la clinique chirurgicale B : A propos de 6 observations. Thèse Med : Rabat, 2008 ; n° 89.
15. Issa Ahmadou. Tumeurs stromales gastro-intestinales (GIST): aspects épidémio-cliniques et thérapeutiques au CHU Gabriel Touré. Thèse. Faculté de médecine et d’Odontostomatologie de Bamako. Mali. 2016 : 146p. https://www.bibliosante.ml/handle/123456789/5295
16. Lv M, Wu C, Zheng Y, Zhao N. Incidence and survival analysis of gastrointestinal stromal tumors in Shanghai: a population-based study from 2001 to 2010. Gastroenterol Res Pract. 2014; 2014:834136. doi: 10.1155/2014/834136. Epub 2014 Apr 23. PMID: 24864136; PMCID: PMC4017880.
17. Ihsane S. Tumeurs stromales gastro-intestinales : Aspects cliniques, anatomopathologiques et moléculaires : Etude rétrospective de 44 cas. Thèse, Université Sidi Mohammed Ben Abdellah 2014.
18. Hinz S, Pauser U, Egberts JH et al. Audit of a series of 40 gastrointestinal stromal tumor cases. European Journal of Surgical Oncology 2006; 32(10): 1125-1129.
19. Al-Than H, El-Menyar A, Rasul KI et al. Clinical presentation, management and outcomes of gastrointestinal Stromal tumors. International Journal of Surgery 2014; 12: 1127-1133.
20. Alberini JL, Al Nakib M, Gontier E et al. Place de l’imagerie par Tomographie par Emissions de Positrons pour les tumeurs stromales gastrointestinales. Gastroentérologie Clinique et Biologique 2007 ; 31 :585-93.
21. Monges G, Bisot-Locard S, Blay JY, et al. The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists. Bulletin de Cancer 2010; 97:10016-22.
22. Duensing A, Heinrich MC, Fletcher CDM, Fletcher JA. Biology of Gastrointestinal Stromal Tumors: KIT Mutations and Beyond. *Cancer Investigation* 2004; *22* (1), 106-116. https://doi.org/10.1081/CNV-120027585.
23. Fukasawa T, Chong JM, Sakurai S et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumors. Jpn J Cancer Res. 2000; 91(12):1241-9. doi: 10.1111/j.1349-7006. 2000.tb00910. x. PMID: 11123422; PMCID: PMC5926300.
24. Chen Y, Tzeng CC, Liou CP, Chang MY, Li CF, Lin CN. Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. J Biomed Sci 2004; 11:64-71.
25. Rabesalama SSEN, Randrianirina A, Rakotonaivo MJ, Rakotoarijoana AH, Rakoto Ratsimba HN. Hémorragie digestive basse : possibilité d’une tumeur stromale rectale. Rev Anesth Réanim Med Urgence 2011 ; 3 :18-20.
26. Landi B, Lecomte T, Cellier C. Tumeurs stromales digestives. *Hépato-Gastro & Oncologie Digestive* 2003 ; *10*(3), 187-196.
27. Rosch T, Lorenz R, Dancygier H, Von Wichert A, Classen M. Endosonographic diagnosis of submucosal upper gastrointestinal tract tumors. Scand J Gastroenterol 1992 ; 27 :1-8.
28. Morelle J, Maassarani F, François P, Dekeuleneer R. Avancées récentes dans la compréhension et la prise en charge des tumeurs stromales gastro-intestinales. *Louvain médical.*2004 ;123(2) :66–74.
29. Casali PG, Blay JY, Abecassis N et al. Gastrointestinal stromal tumors: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2022 Jan; 33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21. PMID: 34560242.
30. Sekkate S, Kairouani M, Abahssain H et al. Tumeurs stromales gastro-intestinales. La presse médicale 2012 ; 41 :917-26.
31. Duensing S, Duensing A. Targeted therapies of gastrointestinal stromal tumors (GIST) The next frontiers. Biochem Pharmacol 2010; 80:575-83.
32. Dei Tos AP, Laurino L, Bearzi I, Messerini L, Farinati F. Gastrointestinal stromal tumors: the histology report. Dig Liver Dis 2011: S304–9.
33. Joensuu H, Rutkowski P, Nishida T et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 2015 Feb 20;33(6):634-42. doi: 10.1200/JCO.2014.57.4970. Epub 2015 Jan 20. PMID: 25605837.
34. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical and molecular genetic features, and differential diagnosis. Virchows Arch 2001, 438:1-12.
35. Mosnier JF. Les tumeurs stromales gastro-intestinales : du gène au traitement. Hépato-Gastro & Oncologie Digestive. 2002 ; 9(6) :403-6.